Pre-Approval Process INAD vs. NADA
|
|
- Poppy Lee
- 8 years ago
- Views:
Transcription
1 Pre-Approval Process INAD vs. NADA Barbara M. Leotta, DVM CVM/ONADE/DTDNFA (240) Pre-Approval Process General Overview Pathways To Legal Marketing Office of New Animal Drug Evaluation (ONADE) Technical Sections Pathways to Legal Marketing Approved New Animal Drug Application (NADA) Traditional Administrative Approved Abbreviated New Animal Drug Application (ANADA) Conditional Approval Index Listing
2 Office of New Animal Drug Evaluation The Office of New Animal Drug Evaluation's (ONADE) major responsibility is to review information submitted by drug sponsors who want to obtain approval to manufacture and market new animal drugs. NADA Background Information What does an approved NADA mean? The product is safe and effective for its intended use The methods, facilities and controls used for the manufacturing, processing and packaging of the drug are adequate to preserve its identity, strength, quality and purity Traditional NADA A complete NADA is composed of the requirements identified in 21 CFR Required information for evaluation of the NADA is grouped into technical sections Technical sections are reviewed concurrently One review clock for entire NADA Outcomes Approval Letter or Incomplete Letter
3 Administrative NADA Submitted after all of the required technical sections have been reviewed by CVM and CVM has issued a technical section complete letter for each of those technical sections under the INAD, phased review process. A final decision on the approval of an application will be made when the Administrative NADA is submitted and CVM evaluates whether all the data for all technical sections viewed as a whole support approval. INAD Phased Review A sponsor may submit data or information in support of a technical section, or a complete technical section, of the NADA for review during the investigation of the new animal drug, i.e., for phased review. INAD Phased Review The same requirements under 21 CFR apply to all NADAs whether for phased review or not. Phasing of technical section submissions is voluntary. The option to phase the review of data submissions applies to all original NADAs and to supplemental NADAs, up to the point at which the sponsor submits an NADA or supplemental NADA.
4 INAD Phased Review Allows sponsors to submit data for review at the most appropriate and productive times in the drug development process rather than submitting all data at one time. INAD Phased Review Provides for protocol review to increase likelihood data will support approval. Submissions containing technical information should be submitted to the investigational new animal drug (INAD) file for direct review by the Division responsible for the technical evaluation. INAD Phased Review The reviewing Division will notify the sponsor in writing of its conclusions on acceptance or non- acceptance of the data submitted relevant to a technical section. If the reviewing Division finds the data for the technical section to be complete, it will issue a technical section complete letter. When CVM finds that all the required sections are complete, the sponsor may file the administrative NADA.
5 Technical Sections Technical requirements of an NADA as defined in Each technical section must support a condition of approval required by CVM. All studies supporting a single technical section should be submitted as well as all other relevant information such as referenced literature, foreign market experience, etc. A technical section should also contain information on the proposed conditions of use and/or labeling, and the relevant portion(s) of the FOI Summary. Technical Sections Major Technical Sections Target Animal Safety Effectiveness Human Food Safety Chemistry, Manufacturing, and Controls Environmental Impact Technical Sections Minor Technical Sections All Other Information Labeling Freedom of Information Summary
6 TAS The Target Animal Safety section must contain full reports of adequate tests by all methods reasonably applicable to show whether or not the new animal drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling. Effectiveness The Effectiveness section must contain full reports of all adequate tests by all methods reasonably applicable to show whether or not the new animal drug is effective as suggested in the proposed labeling. An application may be refused unless it contains substantial evidence consisting of one or more adequate and well-controlled investigations, such as-- Effectiveness A study in a target species A study in laboratory animals Any field investigation A bioequivalence study An in vitro study
7 HFS The Human Food Safety section is submitted only for species that are used for human food. Human Food Safety TOXICOLOGY: determine the no observable effects level (NOEL), acceptable daily intake (ADI), and safe concentration RESIDUE CHEMISTRY: determine the target tissue, marker residue, slaughter withdrawal, and milk withhold times MICROBIAL FOOD SAFETY: evaluate the safety of antimicrobials with regard to their microbiological effects on bacteria of human health concern (Guidance 152 and 159) REGULATORY METHOD: development and validation of methods to measure drug residues in edible tissues CMC The Chemistry, Manufacturing, and Controls section should contain complete information regarding the manufacture of the new animal drug active ingredient and the new animal drug product. Determines whether an animal drug will have and maintain the necessary quality, strength, purity, and identity Methods and controls Stability data GMP compliance
8 Environmental The Environmental Impact section contains either an environmental assessment (EA) under 21 CFR 25.40, or a request for categorical exclusion under 21 CFR or Under 21 CFR 25.15(a), a claim of categorical exclusion must include a statement of compliance with the categorical exclusion criteria and must state that to the sponsor s s knowledge, no extraordinary circumstances exist. AOI The All Other Information section includes all other information, not included in any of the other technical sections, that is pertinent to an evaluation of the safety or effectiveness of the new animal drug for which approval is sought. All other information includes, but is not limited to, any information derived from other marketing (domestic or foreign) and favorable and unfavorable reports in the scientific literature. Labeling The Labeling section should include facsimile copies of container labels, package inserts and any other labeling that will be used with the products. Facsimile labeling is nearly final labeling that adequately reproduces the package size (actual or to scale); graphics; pictures; type size, font, and color of text; and, the substance of the text.
9 FOI Summary The Freedom of Information Summary provides the public a summary of the safety and effectiveness data on which we based our decision to approve the new animal drug. The completed FOI Summary will include the specific language relevant to a technical section that was agreed upon during the review of the individual technical section. FDA/CVM s Responsibilities Protect the Public Health by ensuring safe and effective new animal drugs reach the market unsafe and ineffective new animal drugs do not reach the market Work efficiently to process and review sponsor submissions and applications Meet or Exceed user fee performance goals Work within the limits of statutory authority Thank You!
Guidance for Industry
Guidance for Industry Major, Minor, and Telephone Amendments to Abbreviated New Drug Applications Comments and suggestions regarding this document should be submitted within 90 days of publication in the
More informationVeterinary Compounding
Veterinary Compounding Veterinarians occasionally use compounded preparations to meet a specific patient s medical need. The purpose of this brochure, created jointly by the Animal Health Institute (AHI),
More informationOverview of Pre-Approval Inspections
Overview of Pre-Approval Inspections Presented by: Kelli F. Dobilas NWJ-DO Pre-Approval Manager Pre-Approval Drug Inspections What are Pre-Approval Inspections? One of the last reviews of the drug approval
More information2014 Annual Report on Inspections of Establishments
2014 Annual Report on Inspections of Establishments Table of Contents Introduction... 2 Data Collection and Definitions... 3 Section 510(h)(6)(A)(i) Number of Domestic and Foreign Establishments Registered
More informationCLOSING OUT CONSULTING REVIEWS FOR STARS SUBMISSIONS
CENTER FOR VETERINARY MEDICINE PROGRAM POLICY AND PROCEDURES MANUAL 1243.3029 OFFICE OF NEW ANIMAL DRUG EVALUATION REVIEWER S CHAPTER CLOSING OUT CONSULTING REVIEWS FOR STARS SUBMISSIONS I. Purpose...1
More informationRe: GRAS Notice No. AGRN 000-009
May 4, 2012 Dr. Hardy Edwards III Vitamin Derivatives, Inc. 625 Lem Edwards Road Winterville, Georgia 30683 Re: GRAS Notice No. AGRN 000-009 Dear Dr. Edwards: The Food and Drug Administration (FDA) is
More informationPost-Approval Change Management: Challenges and Opportunities An FDA Perspective
CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,
More informationGuidance for Industry
Guidance for Industry Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products For questions on the content of the guidance,
More informationGLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com
GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com Common Misconception Good Laboratory Practices 1) A quality system concerned with the organizational process
More informationPreparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant
Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives Barry A. Friedman, Ph.D. Consultant FDA Overview FDA is a consumer protection agency within the Department of Health & Human
More informationAdjuvants and Excipients
Adjuvants and Excipients The Food Safety and Inspection Service (FSIS) transferred the official responsibility to evaluate adjuvants and excipients used in Veterinary Biologics back to the Animal and Plant
More informationFebruary 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
More informationOverview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
More informationREPORT FOR INTERNATIONAL COOPERATION ON COSMETIC REGULATION (ICCR)
REPORT FOR INTERNATIONAL COOPERATION ON COSMETIC REGULATION (ICCR) Principles for the handling of traces of impurities and/or contaminants in cosmetic products Report is: 1 [Choose One] Prepared For ICCR
More informationBiosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009
Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry DRAFT GUIDANCE This guidance document is being
More informationGuidance for Industry
Guidance for Industry Submitting Debarment Certification Statements DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
More informationGuidance for Industry Time and Extent Applications for Nonprescription Drug Products
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
More informationInformation Sheet Guidance For IRBs, Clinical Investigators, and Sponsors
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors FDA Institutional Review Board Inspections Additional copies are available from: Office of Good Clinical Practice Office of Special
More information4.1 Objectives of Clinical Trial Assessment
L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical
More informationWorking with ICH Quality Guidelines - the Canadian Perspective
Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction
More informationGuidance for Industry
#171 Guidance for Industry Waivers of In Vivo Demonstration of Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form Products and Type A Medicated Articles (This version of the guidance replaces
More informationGuidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More informationComparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLP
Comparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLP Document issued on: June 2004 U.S. Department of Health and Human Services Food and Drug Administration
More informationFormal FDA Meeting Request: Guidance and Template
Formal FDA Meeting Request: Guidance and Template ICTR Navigators July 23, 2011 Version 2.0 Page 1 of 20 1.0 Table of Contents Section Page 1.0 Table of Contents 2 2.0 Abbreviations 2 3.0 FDA Regulations
More informationRoles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
More informationCODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE CAC/RCP 61-2005
CAC/RCP 61-2005 Page 1 of 15 CODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE CAC/RCP 61-2005 INTRODUCTION... 2 AIMS AND OBJECTIVES... 2 RESPONSIBILITIES OF THE REGULATORY AUTHORITIES...
More informationA FDA Perspective on Nanomedicine Current Initiatives in the US
A FDA Perspective on Nanomedicine Current Initiatives in the US Carlos Peña, PhD Office of the Commissioner FDA September 3, 2010 Outline Context Nanotechnology Task Force report summary Identification
More informationGuidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA
Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationThomas Hinchliffe, Pharm.D. CDR, U.S. Public Health Service Special Assistant to the Director Office of Generic Drugs Food and Drug Administration
Thomas Hinchliffe, Pharm.D. CDR, U.S. Public Health Service Special Assistant to the Director Office of Generic Drugs Food and Drug Administration Disclaimer & Disclosure Views presented are those of the
More informationRegulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
More informationGuidance for Industry Certification Process for Designated Medical Gases
Guidance for Industry Certification Process for Designated Medical Gases DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
More informationPRINCIPLES AND GUIDELINES FOR THE EXCHANGE OF INFORMATION IN FOOD SAFETY EMERGENCY SITUATIONS
PRINCIPLES AND GUIDELINES FOR THE EXCHANGE OF INFORMATION IN FOOD SAFETY EMERGENCY SITUATIONS SECTION 1 PREAMBLE CAC/GL 19-1995 1. When a food safety emergency arises, in order to minimize potential adverse
More informationANALYTICAL OUTSOURCING WHY SHOULD YOU OUTSOURCE?
ANALYTICAL OUTSOURCING WHY SHOULD YOU OUTSOURCE? The choice to outsource is a somewhat difficult decision, but it is one that can be both analytically and financially rewarding. By carefully considering
More informationImporting pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
More informationFAILURE TO WARN PRODUCTS LIABILITY FOR MANUFACTURERS OF FDA-APPROVED DRUGS by Kathrin Chambers
FAILURE TO WARN PRODUCTS LIABILITY FOR MANUFACTURERS OF FDA-APPROVED DRUGS by Kathrin Chambers Submitted in partial fulfillment of the requirements of the King Scholar Program Michigan State University
More informationExtemporaneously Prepared Early Phase Clinical Trial Materials
Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS, RAC Eli Lilly & Co. Regulatory Advisor International Consortium for Innovation & Quality in Pharmaceutical Development
More informationPOLICY AND PROCEDURES OFFICE OF NEW DRUGS. NDAs and BLAs: Communication to Applicants of Planned Review Timelines.
CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 6010.8 Rev. 1 POLICY AND PROCEDURES OFFICE OF NEW DRUGS NDAs and BLAs: Communication to Applicants of Planned Review Timelines Table of Contents PURPOSE...1
More informationConsolidated TEXT CONSLEG: 1991L0414 01/01/2004. produced by the CONSLEG system. of the Office for Official Publications of the European Communities
EN Consolidated TEXT produced by the CONSLEG system of the Office for Official Publications of the European Communities CONSLEG: 1991L0414 01/01/2004 Number of pages: 194 < Office for Official Publications
More informationBiobanking Pluripotent Stem Cell Lines: UK and EU regulations Glyn Stacey, UK Stem Cell Bank, NIBSC
Biobanking Pluripotent Stem Cell Lines: UK and EU regulations Glyn Stacey, UK Stem Cell Bank, NIBSC ISCT Conference, New Zealand, April 2013 April 1 st 2013 NIBSC will become part of the Medicines and
More informationGuidance for Industry
Guidance for Industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products Center for
More informationCombination Products Regulation in the United States
Combination Products Regulation in the United States Presenter: Scott Sardeson RAC US/EU 3M Health Care St. Paul, MN USA 1 Presentation Outline Combination products Definitions and Regulations Jurisdiction
More informationRisk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry The portion of this guidance document setting forth the submission procedures for risk evaluation and mitigation
More informationCombination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma
Combination Products Presented by: Karen S. Ginsbury For: IFF March 2014 Types of products Biological and medical device (freeze dried + syringe dual volume) Medical device and plasma devised product (syringe)
More informationThe Antimicrobial Susceptibility Testing Device Manufacturer: Development Process, Timelines, and Challenges
The Antimicrobial Susceptibility Testing Device Manufacturer: Development Process, Timelines, and Challenges Sheila Farnham, MT(ASCP) President Susceptibility Testing Manufacturers Association January
More informationGuidance for Industry and FDA Staff
Guidance for Industry and FDA Staff Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution
More informationAnnex 7 Guidelines on pre-approval inspections
World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for the
More informationApplication of Clinical Trial Certificate of Chinese Medicines in Hong Kong
Application of Clinical Trial Certificate of Chinese Medicines in Hong Kong D R. K F C H U N G D E P A R T M E N T O F P S Y C H I A T R Y U N I V E R S I T Y O F H O N G K O N G ( S E P T 2 0 1 4 ) Evidence-based
More informationGuidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More information3 Food Standards Agency, London, UK
Chapter six From Hazard to Risk e Assessing the Risk Charlotte Bernhard Madsen 1, Geert Houben 2, Sue Hattersley 3, Rene W.R. Crevel 4, Ben C. Remington 5, Joseph L. Baumert 5 1 DVM Research Leader Division
More informationGuidance for Industry
5 Guidance for Industry Drug Stability Guidelines (This version of the guidance replaces the version that was made available in December 1990. This guidance document has been revised to correct the contact
More informationCosmetics Safety Bill Would Incorporate TSCA Bill Provisions
Beveridge & Diamond, P.C., August 2, 2010 Regulation of cosmetics by the Food and Drug Administration ( FDA ) would be thoroughly overhauled under a bill introduced on July 20, 2010, the Safe Cosmetics
More informationPremarket Approval Applications (PMAs), Product Development Protocols (PDPs), and Humanitarian Device Exemptions
FDLI s Introduction to Medical Device Law and Regulation: Understanding How FDA Regulates the Medical Device Industry October 28-29, 2002 The Westin Grand Hotel Washington, D.C. Premarket Approval Applications
More informationIntroduction to Compliance with FDA Labeling and Advertising Requirements
Introduction to Compliance with FDA Labeling and Advertising Requirements Second Annual Pharmaceutical Industry Regulatory and Compliance Summit Dick Kenny FDA History Basic function of government Oldest
More informationCleaning Validation in Active pharmaceutical Ingredient manufacturing plants
Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants September 1999 Table of contents 1. Foreword...... 2 2. Objective...... 3 3. Scope........ 4 4. Potential residues... 5 5. Current
More informationU.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC
Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions
More informationGuidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions
Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions U.S. Department of Health and Human Services Food and Drug Administration
More informationSERVICES FOR. Devices and Combination Products
SERVICES FOR Devices and Combination Products How to Contact Us U.S. FACILITIES / CLIENT SERVICES St. Paul 2540 Executive Drive St. Paul, MN 55120 FAX 651.675.2005 Atlanta 1265 Kennestone Circle Marietta,
More informationFAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration
More informationQuality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:
NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a
More informationNDA 021879 NDA APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021879 NDA APPROVAL Avanir Pharmaceuticals Attention: Randall Kaye, M.D. Vice President, Clinical and Medical
More informationFDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF GLOBAL AND REGULATORY OPERATIONS AND POLICY
SMG 1312.4 FDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF GLOBAL AND REGULATORY OPERATIONS AND POLICY OFFICE OF REGULATORY AFFAIRS OFFICE OF OPERATIONS
More informationBIOTECHNOLOGY OPERATIONS
BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press
More informationMinnesota Board of Pharmacy. Guidance on the Compounding of Veterinary Products Approved: March 4, 2015
EXECUTIVE SUMMARY Minnesota Board of Pharmacy Guidance on the Compounding of Veterinary Products Approved: March 4, 2015 Board staff has held several meetings with representatives of the Minnesota Veterinary
More informationFDA Inspection Observations The FDA 483 and Beyond. Objectives
FDA Inspection Observations The FDA 483 and Beyond Presenter: David L. Chesney Vice President and Practice Lead PAREXEL Consulting, Waltham, MA Dave.chesney@parexel.com Objectives Describe history and
More informationUS Regulations for Import and Export of Cell Therapy Products
US Regulations for Import and Export of Cell Therapy Products Kurt Gunter, MD U Minnesota UCB Transplants (2001-2007)* Total units: 790 Number US banks: 19 Number non-us banks: 12 % units from non-us banks:
More informationCMC Writing for IND Applications. David H. McKenna, Jr., M.D. University of Minnesota April 10-11, 2007 Workshop
CMC Writing for IND Applications David H. McKenna, Jr., M.D. University of Minnesota April 10-11, 2007 Workshop CMC Writing for IND Applications ~Outline~ What is the CMC section? Who writes the CMC section?
More informationSECTION 6. The Codex code of practice on good animal feeding
SECTION 6 The Codex code of practice on good animal feeding 60 The Codex code of practice on good animal feeding SECTION 6 61 CODE OF PRACTICE ON GOOD ANIMAL FEEDING CAC/RCP 54-2004 SECTION 1. INTRODUCTION
More informationGuidance for Industry
Guidance for Industry Process Validation: General Principles and Practices U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
More informationFDA LACKS COMPREHENSIVE DATA TO DETERMINE WHETHER RISK EVALUATION AND MITIGATION STRATEGIES IMPROVE DRUG SAFETY
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL FDA LACKS COMPREHENSIVE DATA TO DETERMINE WHETHER RISK EVALUATION AND MITIGATION STRATEGIES IMPROVE DRUG SAFETY Daniel R. Levinson Inspector
More informationDisclaimer: The following transcript is a draft and is pending review for accuracy by the speakers. Edits have been made for clarity.
Want to comment? Your input is important. OLAW welcomes questions and comments from viewers of this recording. OLAW will post the comments, questions, and answers on the OLAW website. Please go to the
More informationCATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity
CATEGORY Advertising Guidance Agenda: New & Guidances CDER is Planning to Publish During Calendar Year 2016 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details
More informationTopics for today. Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports. Post-marketing Submissions
Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports Martha A. Feldman, RAC Drug & Device Development Co., Inc. Topics for today Post-approval requirements for
More informationFrequently asked questions on the procedure for the re-assessment of glyphosate within the framework of the EU active substance review
Frequently asked questions on the procedure for the re-assessment of glyphosate within the framework of the EU active substance review BfR FAQ, 12 November 2015 Active substances used in pesticides are
More informationOverview on EFSA data requirements for the safety evaluation of food enzymes applications
Overview on EFSA data requirements for the safety evaluation of food enzymes applications Fidel Toldrá and Klaus-Dieter Jany EFSA CEF Panel Info session on Food Enzymes applications Parma, 27 May 2014
More informationtdodds@jeffyuen.com 714 282-1014 Jeff Yuen and Associates, Inc. PO Box 6026 Orange, CA 92863 Terri Dodds CAPT. (RET) TERRI L.
SKILLS/SPECIAL QUALIFICATIONS: Regulatory Expertise: Technical Expertise: CAPT. (RET) TERRI L. DODDS - BSN, RN Former Public Health Service (PHS) Officer with 16 years of FDA experience in Pharmaceuticals,
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications DRAFT GUIDANCE This guidance document is being distributed
More informationGuidance for Industry
Guidance for Industry Providing Regulatory Submissions in Electronic Format Drug Establishment Registration and Drug Listing U.S. Department of Health and Human Services Food and Drug Administration Office
More informationGuidance for Industry Computerized Systems Used in Clinical Investigations
Guidance for Industry Computerized Systems Used in Clinical Investigations U.S. Department of Health and Human Services Food and Drug Administration (FDA) Office of the Commissioner (OC) May 2007 Guidance
More informationGeneric Drug User Fee Act Program Performance Goals and Procedures
Generic Drug User Fee Act Program Performance Goals and Procedures The performance efficiencies, metric goals and procedures to which FDA will agree upon commencement of a generic drug user fee act (GDUFA)
More informationRegulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials
Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Ron Hinkel, Director Quality Systems BioReliance Inc. Patti Rossman, President Globiox Purpose Keep pace
More informationProviding Regulatory Submissions In Electronic Format Standardized Study Data
Providing Regulatory Submissions In Electronic Format Standardized Study Data Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationRegulatory Submission: Applying GLP in Surgical Efficacy Studies
Regulatory Submission: Applying GLP in Surgical Efficacy Studies Curtis Schondelmeyer, DVM Director Preclinical Veterinary Services and Efficacy and Surgical Research Services Welcome to Toxikon 2 CONFIDENTIAL
More informationIND Process and Review Procedures (Including Clinical Holds) CONTENTS
MANUAL OF POLICIES AND PROCEDURES CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 6030.1 REVIEW MANAGEMENT IND Process and Review Procedures (Including Clinical Holds) CONTENTS PURPOSE REFERENCES DEFINITIONS
More informationGuidance for Industry and Food and Drug Administration Staff
Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff Guidance for Industry and Food and Drug Administration Staff Document
More informationGuidance for Industry PAT A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance
Guidance for Industry PAT A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance U.S. Department of Health and Human Services Food and Drug Administration Center for
More informationFOOD AND DRUG LAW JOURNAL Analyzing the Laws, Regulations, and Policies Affecting FDA-Regulated Products
FOOD AND DRUG LAW JOURNAL Analyzing the Laws, Regulations, and Policies Affecting FDA-Regulated Products Enforcement Protecting the Public s Health Through the Application Integrity Policy Paula R. Katz
More informationComparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
More informationPHARMACOVIGILANCE GUIDELINES
PHARMACOVIGILANCE GUIDELINES What is Pharmacovigilance? Pharmacovigilance is defined as the science and activities concerned with the detection, assessment, understanding and prevention of adverse reactions
More informationNRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1
NRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1 2 The National Agency of Drug and Food Control (NA-DFC) is a non departmental
More informationThe statements made herein are our own and do not necessarily reflect the views of the Johns Hopkins University.
Johns Hopkins Center for a Livable Future 615 North Wolfe Street, W7010 Baltimore, MD 21205 January 4, 2013 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm.
More informationGuidance for Industry
Guidance for Industry Medication Guides Adding a Toll-Free Number for Reporting Adverse Events U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Jabones Pardo S.A.
More informationSanitation Standard Operating Procedures (SOPs)
Sanitation Standard Operating Procedures (SOPs) I. Objective of Proposal The objectives of the sanitation standard operating procedures (SOP) provisions clarify that plant management is responsible for
More informationQuality Considerations for Breakthrough Therapies-FDA Perspective
Quality Considerations for Breakthrough Therapies-FDA Perspective DIA June 17, 2014 Ramesh K. Sood, Ph.D. Acting Division Director and Angelica Dorantes, Ph.D. xxx ONDQA/OPS/CDER/FDA 1 Background Outline
More informationGuidance for Industry ANDAs: Stability Testing of Drug Substances and Products
Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationCorn Oil Extraction Optimization. Essential Expertise for Water, Energy and Air SM
Corn Oil Extraction Optimization 1 COE Optimization - Overview Technology review TSC & GR 8109 Product development Chemistry Not an equipment solution. Production improvements Both centrifuge types benefit
More informationInvestigational Drugs: Investigational Drugs and Biologics
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place
More informationChanges to an Approved Product
Changes to an Approved Product Chemistry, Manufacturing and Controls By Khandan Baradaran, PhD and Peggy Berry, MBA, RAC It is a huge achievement for any company to obtain licensing rights to an approved
More informationGuidance for Industry Consumer-Directed Broadcast Advertisements
Guidance for Industry Consumer-Directed Broadcast Advertisements U.S. Department of Health and Human Services Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research
More information